Rapport Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Rapport Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Rapport Therapeutics, Inc. Common Stock (RAPP) has a Cash Flow-to-Debt Ratio of -1.51x as of June 2026, meaning its operating cash flow of $-54.52 Million could theoretically repay -2% of its total liabilities ($36.06 Million) in one year. See RAPP financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Rapport Therapeutics, Inc. Common Stock (2022–2025)
Cash flow-to-debt ratio of Rapport Therapeutics, Inc. Common Stock from 2022 to 2025. Historical debt coverage capacity for Rapport Therapeutics, Inc. Common Stock across 4 annual periods. Also explore how fast is Rapport Therapeutics, Inc. Common Stock growing its equity to track the company's year-over-year net asset growth rate.
Rapport Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2025)
Rapport Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Rapport Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see RAPP cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.15x | $-87.47 Million | $27.78 Million | ▲ +53.8% |
| 2024 | -6.82x | $-64.83 Million | $9.51 Million | ▼ -4442.7% |
| 2023 | -0.15x | $-27.18 Million | $181.06 Million | ▲ +44.0% |
| 2022 | -0.27x | $-3.24 Million | $12.10 Million | — |